Compare Cardinal Health Inc (CAH) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Nuscale Power Corporation — how do they compare? Cardinal Health Inc trades at $234.16 (market cap $55.88B), while Nuscale Power Corporation trades at $9.62 (market cap $4.06B). The key difference: Cardinal Health Inc is far larger — about 13.8× Nuscale Power Corporation's market cap, and Cardinal Health Inc pays a 0.86% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| CAH | SMR | |
|---|---|---|
Market Cap | $55.88B | $4.06B |
Sector | Health | Utilities |
52-Week High | $240.26 | $53.43 |
52-Week Low | $146.04 | $7.59 |
Enterprise Value | $59.91B | $2.99B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
NuScale Power (SMR) trades at $9.58, up 4.36% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net margin of -3,888.7%. Recent news highlights regulatory progress for its small modular reactors and potential from AI data center power demand, though revenue plunged 98.8% year-over-year in Q2 2026.
Outlook hinges on commercial deployment success, with a consensus price target of $10.50 offering 9.6% upside. High execution risk and cash burn are key concerns, but analyst sentiment is 50% buy-rated. Investors face volatility from project timelines versus speculative growth potential in nuclear energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
